ClinicalTrials.gg
Not yet recruitingNCT06799039Updated Nov 16, 2026

Pilot Trial of Xylitol for C. Difficile De-Colonization in Patients With Inflammatory Bowel Disease

An Early Phase 1 interventional study of Xylitol in Inflammatory Bowel Disease (IBD) and Clostridioides Difficile Infection, sponsored by Brigham and Women's Hospital. Not yet recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-16.

Sponsored by Brigham and Women's Hospital · Early Phase 1, Interventional, and Treatment

How we know

Updated Nov 16, 2026Start date movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Early Phase 1
Study type
Interventional
Enrollment
69
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 463 studies in Inflammatory Bowel Diseases with a site in United States — 103 open to participants now, 124 under way, 6 of them phase 3. Inflammatory Bowel Diseases · United States.

Planned enrollment
135th of 327
69 · median 50
Started
2027
with 3 others
Phase 1
44 of 463
6 open now
Primary completion
2030-09
later than 105 of 121 live
Registered
418th of 463
by date
Lead sponsor
8 of 463
Brigham and Women's Hospital

Among the 463 studies in Inflammatory Bowel Diseases with a site in United States, this one is the 135th largest by planned enrollment of the 327 interventional ones that give a count, is one of 4 that started in 2027, is one of 44 in phase 1, reaches primary completion later than 105 of the 121 other live ones, and was the 418th registered.

Inflammatory Bowel Diseases

1,555 studies on the registry are indexed under Inflammatory Bowel Diseases; 425 are open to participants now.

Browse Inflammatory Bowel Diseases studies →

Open to participants now

103 of the 463 studies in Inflammatory Bowel Diseases with a site in United States are open now. Recruiting first, the newest first:

98 more — sign in →

All 103 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 276 Inflammatory Bowel Diseases studies recruiting now, 134 (49%) set no upper age limit and 114 (41%) stop at 75 or younger; 75 take children under 18; 60 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 463 studies in Inflammatory Bowel Diseases with a site in United States, or all of them as a file.
02

Study summary

This 3+3 dose escalation pilot trial will assess the safety and efficacy of xylitol as an oral therapeutic for decolonization of C. difficile in the Inflammatory Bowel Disease (IBD) patient population.

Read the detailed description

Participants with confirmed IBD diagnosis who are scheduled for an outpatient colonoscopy for any reason at Brigham and Women's Hospital will be eligible for enrollment. Participants will be screened for C. difficile colonization via colonic wash sampling during colonoscopy. Participants may only have inactive or mild IBD at the time of the colonoscopy to be eligible.

Eligible participants will be initially enrolled in the observational cohort until there are 39 subjects enrolled. Participants in the observational cohort will be assessed at Week 1, 4 and 8, following confirmation of colonization. Participants will only be assessed for stool sample testing, IBD scoring and occurrence of CDI.

The subsequent participants who meet eligibility criteria will be enrolled into one of five consecutively increasing dosing groups of xylitol. The dose A treatment arm will receive a daily dose of 1 gram of xylitol for 7 days. The dose B treatment arm will receive a daily dose of 2 grams of xylitol for 7 days. The dose C treatment group will receive a daily dose of 5 grams of xylitol for 7 days. The dose D treatment group will receive a daily dose of 7 grams of xylitol for 7 days. The dose E treatment group will receive a daily dose of 9 grams of xylitol for 7 days. Participants will end dosing at day 7 but monitoring will continue through to week 8.

Participants in the will be assessed through week 8 for the primary outcome, determining the maximum tolerated dosage of xylitol. C. difficile decolonization will be assessed through week 8. Participants will also receive weekly phone call for assessment of symptoms and tolerability through week 8. In addition, secondary efficacy outcomes including IBD disease activity and development of CDI will be evaluated at week 8, and week 26. Participants will also be followed through week 26 for long-term safety, efficacy, and clinical outcomes. Disease activity and symptoms will be recorded from informed consent through the week 26 trial visit.

The primary outcome, determining the maximum tolerated dose of xylitol at week 8 will be confirmed via adverse event reporting. Additional C. difficile testing will be done at week 26.

The study will prospectively enroll between 15 and 30 adult participants at a single center. Participants that experience intolerable adverse events will be withdrawn from the study and will be considered treatment failures.

03

Conditions studied

  • Inflammatory Bowel Disease (IBD)
  • Clostridioides Difficile Infection

Keywords

  • C. Difficile
  • Decolonization
  • IBD
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Signed .
  2. Male or female ≥ 18 years of age
  3. IBD diagnosis (CD, UC or indeterminant Colitis will be permitted)
  4. Inactive or mild IBD (HBI score ≤ 4; Partial Mayo score ≤ 4)
  5. Presenting for outpatient colonoscopy or clinic appointment

Exclusion criteria

Exclusion Criteria:

  1. Unable to provide consent.
  2. Patients with previous colectomy, ostomy, J-pouch, or previous colon surgery (excluding appendectomy)
  3. Unable to complete study procedures.
  4. Chronic use of antibiotics.
  5. Inability or unwillingness to swallow capsules.
  6. Allergy to xylitol.
  7. Currently pregnant or breastfeeding
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Early Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
69 participants (estimated)

Study arms

  • Experimental
    Dose Finding Cohort

    One of five consecutively increasing dosing groups of xylitol

    Drug: Xylitol

  • No intervention
    Observational Cohort

    Participants will be assessed for rates of spontaneous decolonization, stool sample testing and IBD scoring.

Interventions

  • Xylitol is a sugar alcohol and considered a GRAS substance by the FDA. Patients will be consecutively enrolled into one of five dosing including 1g, 2g, 5g, 7g and 9g.

06

What researchers measure

Primary outcomes

  1. Safety and Efficacy of Xylitol

    Incidence of Treatment Emergent Adverse Events (TEAEs) through Week 8

    Time frame: 8 weeks

  2. C. Diff Decolonization

    Proportion of patients decolonized of C. difficile at Week 8

    Time frame: 8 weeks

Secondary outcomes

  1. Biomass of C. Difficile

    Change in biomass of C. difficile in patients at Week 8

    Time frame: 8 weeks

  2. Effect of C. difficile decolonization on Inflammatory Bowel Disease (IBD) clinical outcomes

    Change in IBD clinical score at Week 8 and Week 26. IBD clinical scores are used to assess IBD patient symptoms. The assessments are separated between scores for Ulcerative Colitis (UC) and Crohn's Disease (CD). The Harvey Bradshaw Index (HBI) is a clinical assessment for IBD patients with Crohn's disease while Partial Mayo Score is a clinical assessment for Ulcerative Colitis. The scores will be collected at study visit in form of a survey. The HBI score can vary but a score above 8 or 9 is considered severe disease activity. The Partial Mayo Score can range from 0 to 9 and a score above 7 is considered severe disease activity. A decrease in score from baseline to follow-up timepoints is indicative of improved IBD patient symptoms.

    Time frame: 26 weeks

  3. C. Difficile infection surveillance

    Incidence of patients developing C. Difficile Infection through Week 26

    Time frame: 26 weeks

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Mar 2027; primary completion for Sep 2030, 42 months later.

Of 51 phase 1 interventional studies under Inflammatory Bowel Diseases, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 30. This study's planned 42 months is above that.

Start moved once since we started tracking on Sep 25, 2026: Sep 2026 → Mar 2027, on Nov 16, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jan 23, 2025
First posted
Jan 29, 2025
StartEst.
Mar 1, 2027was Sep 2026
Primary completionEst.
Sep 1, 2030
CompletionEst.
Sep 1, 2031
Last update
Nov 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Start date
Sep 1, 2026→Mar 1, 2027
Nov 16, 2026
Show all 1 update
  1. Nov 16, 2026
    Start date Sep 1, 2026→Mar 1, 2027
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06799039
Responsible party
Jessica Ravikoff Allegretti (Jessica R. Allegretti, MD, MPH, FACG, AGAF, Principle Investigator, Brigham and Women's Hospital) — Principal investigator
First posted
Jan 29, 2025
Start date
Mar 1, 2027 (estimated)
Primary completion
Sep 1, 2030 (estimated)
Completion
Sep 1, 2031 (estimated)
Last update
Nov 16, 2026

Study contacts

Heidy Cabral
Contact
hjcabral@bwh.harvard.edu
617-525-7322
Jessica Allegretti, MD MPH
Contact
617-732-6389
Jessica Allegretti, MD MPH
principal investigator · Brigham and Women's Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Xylitol

Start the discussion